Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

Clinical trial NCT02761070 · COMPLETED

Trial details

NCT number: NCT02761070
Sponsor: Kyorin University
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Glioblastoma Recurrence Progression

Start date: 2016-07-11
Primary completion: 2025-04-17
Enrollment: 146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.